Sign In
Buy AKZOY
Akzo Nobel N.V. (ADR) Earnings Calls
| Release date | Apr 22, 2026 |
| EPS estimate | $0.300 |
| EPS actual | $0.350 |
| EPS Surprise | 16.67% |
| Revenue estimate | 2.734B |
| Revenue actual | 2.796B |
| Revenue Surprise | 2.25% |
| Release date | Feb 03, 2026 |
| EPS estimate | $0.290 |
| EPS actual | $0.220 |
| EPS Surprise | -24.14% |
| Revenue estimate | 2.868B |
| Revenue actual | 2.797B |
| Revenue Surprise | -2.49% |
| Release date | Oct 22, 2025 |
| EPS estimate | $0.400 |
| EPS actual | $0.390 |
| EPS Surprise | -2.50% |
| Revenue estimate | 2.492B |
| Revenue actual | 2.957B |
| Revenue Surprise | 18.68% |
| Release date | Jul 22, 2025 |
| EPS estimate | $0.470 |
| EPS actual | $0.430 |
| EPS Surprise | -8.51% |
| Revenue estimate | 2.665B |
| Revenue actual | 3.092B |
| Revenue Surprise | 16.00% |
Last 4 Quarters for Akzo Nobel N.V. (ADR)
Below you can see how AKZOY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 22, 2025 |
| Price on release | $22.64 |
| EPS estimate | $0.470 |
| EPS actual | $0.430 |
| EPS surprise | -8.51% |
| Date | Price |
|---|---|
| Jul 16, 2025 | $23.22 |
| Jul 17, 2025 | $23.07 |
| Jul 18, 2025 | $22.99 |
| Jul 21, 2025 | $23.05 |
| Jul 22, 2025 | $22.64 |
| Jul 23, 2025 | $23.07 |
| Jul 24, 2025 | $22.79 |
| Jul 25, 2025 | $23.02 |
| Jul 28, 2025 | $22.32 |
| 4 days before | -2.50% |
| 4 days after | -1.41% |
| On release day | 1.90% |
| Change in period | -3.88% |
| Release date | Oct 22, 2025 |
| Price on release | $23.49 |
| EPS estimate | $0.400 |
| EPS actual | $0.390 |
| EPS surprise | -2.50% |
| Date | Price |
|---|---|
| Oct 16, 2025 | $23.67 |
| Oct 17, 2025 | $23.91 |
| Oct 20, 2025 | $23.77 |
| Oct 21, 2025 | $23.52 |
| Oct 22, 2025 | $23.49 |
| Oct 23, 2025 | $23.49 |
| Oct 24, 2025 | $23.52 |
| Oct 27, 2025 | $23.57 |
| Oct 28, 2025 | $23.46 |
| 4 days before | -0.760% |
| 4 days after | -0.149% |
| On release day | 0% |
| Change in period | -0.91% |
| Release date | Feb 03, 2026 |
| Price on release | $22.29 |
| EPS estimate | $0.290 |
| EPS actual | $0.220 |
| EPS surprise | -24.14% |
| Date | Price |
|---|---|
| Jan 28, 2026 | $23.29 |
| Jan 29, 2026 | $23.61 |
| Jan 30, 2026 | $23.21 |
| Feb 02, 2026 | $23.20 |
| Feb 03, 2026 | $22.29 |
| Feb 04, 2026 | $23.38 |
| Feb 05, 2026 | $23.30 |
| Feb 06, 2026 | $23.03 |
| Feb 09, 2026 | $23.34 |
| 4 days before | -4.29% |
| 4 days after | 4.71% |
| On release day | 4.89% |
| Change in period | 0.215% |
| Release date | Apr 22, 2026 |
| Price on release | $20.79 |
| EPS estimate | $0.300 |
| EPS actual | $0.350 |
| EPS surprise | 16.67% |
| Date | Price |
|---|---|
| Apr 16, 2026 | $20.46 |
| Apr 17, 2026 | $21.17 |
| Apr 20, 2026 | $20.87 |
| Apr 21, 2026 | $20.18 |
| Apr 22, 2026 | $20.79 |
| Apr 23, 2026 | $20.42 |
| Apr 24, 2026 | $20.44 |
| Apr 27, 2026 | $20.49 |
| Apr 28, 2026 | $19.59 |
| 4 days before | 1.59% |
| 4 days after | -5.77% |
| On release day | -1.78% |
| Change in period | -4.27% |
Akzo Nobel N.V. (ADR) Earnings Call Transcript Summary of Q1 2026
Akzo Nobel reported a stronger-than-expected Q1 2026: adjusted EBITDA was €345m, 7% above consensus, and the adjusted EBITDA margin expanded to 14.5% (up 80bps). Organic sales were down 1% (volumes -1%, price +1%, mix -1%), with a mixed regional performance—Asia and South America showing strength while North America and Europe remained soft. Deco outperformed (notably Asia and Latin America) and delivered significant margin expansion (+300bps) driven by pricing and structural cost savings. The company continues its industrial transformation (15 sites closed to date; more closures planned) and completed the sale of its Pakistan Deco business (~€50m enterprise value, ~14x EBITDA). Financing was strengthened with a €1.1bn dual-tranche bond issued in March and net leverage stayed around ~2x. Management warned of expected high‑teens raw material inflation for the remainder of the year due to Middle East tensions and has announced price increases (mix of list increases and surcharges) intended to fully offset the inflation; pricing impact will ramp through Q2 and be fully visible in Q3. Akzo Nobel maintained its 2026 adjusted EBITDA target of at or above €1.7bn (including a €100m step-up driven by €90m net savings from the industrial program) and expects Q2 adjusted EBITDA of about €400m. Cash flow improved sequentially (free cash flow -€144m vs -€183m a year ago) and working capital management shows progress (WC 16.8%). Merger preparations with Axalta are on track (PCAOB audit complete, confidential F-4 filed); closing expected by year-end or early next year.
